Skip to main content
SpringerLink
Log in

Pathology of Prostate Cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cookson MS: Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol 4(3): 93–97, discussion 99, 2000

    Google Scholar 

  2. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 50(3): 125–128, 1966

    Google Scholar 

  3. Kovi J: Microscopic differential diagnosis of small acinar adenocarcinoma of prostate. Pathol Annu 20(Pt 1): 157–196, 1985

    Google Scholar 

  4. Mostofi FK, Sesterhenn IA et al.: Prostatic carcinoma: Problems in the interpretation of prostatic biopsies. Hum Pathol 23(3): 223–241, 1992

    Google Scholar 

  5. Ro JY, Grignon DJ, Amin MB, Ayala A: Atlas of Surgical Pathology of the Male Reproductive Tract, W. B. Saunders Co., Philadelphia, 1997

    Google Scholar 

  6. Kramer CE, Epstein JI: Nucleoli in low-grade prostate adenocarcinoma and adenosis. Hum Pathol 24(6): 618–623, 1993

    Google Scholar 

  7. Epstein JI: Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 26(2): 223–229, 1995

    Google Scholar 

  8. Carstens PH: Perineural glands in normal and hyperplastic prostates. J Urol 123(5): 686–688, 1980

    Google Scholar 

  9. Algaba F, Epstein JI, et al.: Assessment of prostate carcinoma in core needle biopsy–definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 78(2): 376–381, 1996

    Google Scholar 

  10. Taylor NS: Histochemistry in the diagnosis of early prostatic carcinoma. Hum Pathol 10(5): 513–520, 1979

    Google Scholar 

  11. Ro JY, Grignon DJ et al.: Mucin in prostatic adenocarcinoma. Semin Diagn Pathol 5(3): 273–283, 1988

    Google Scholar 

  12. Pinder SE, McMahon RF: Mucins in prostatic carcinoma. Histopathology 16(1): 43–46, 1990

    Google Scholar 

  13. Epstein JI, Fynheer J: Acidic mucin in the prostate: Can it differentiate adenosis from adenocarcinoma? Hum Pathol 23(12): 1321–1325, 1992

    Google Scholar 

  14. Grignon DJ, Ro JY, et al.: Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate gland: An immunohistochemical study. Hum Pathol 19(12): 1425–1433, 1988

    Google Scholar 

  15. Grignon DJ, Ro JY, et al.: Sclerosing adenosis of the prostate gland. A lesion showing myoepithelial differentiation. Am J Surg Pathol 16(4): 383–391, 1992

    Google Scholar 

  16. Grignon DJ, O'Malley FP: Mucinous metaplasia in the prostate gland. Am J Surg Pathol 17(3): 287–290, 1993

    Google Scholar 

  17. Goldstein NS, Qian J, et al.: Mucin expression in atypical adenomatous hyperplasia of the prostate. Hum Pathol 26(8): 887–891, 1995

    Google Scholar 

  18. Jensen PE, Gardner WA Jr, et al.: Prostatic crystalloids: Association with adenocarcinoma. Prostate 1(1): 25–30, 1980

    Google Scholar 

  19. Ro JY, Ayala AG et al.: Intraluminal crystalloids in prostatic adenocarcinoma. Immunohistochemical, electron microscopic, and x-ray microanalytic studies. Cancer 57(12): 2397–2407, 1986

    Google Scholar 

  20. Ro JY, Grignon DJ et al.: Intraluminal crystalloids in whole-organ sections of prostate. Prostate 13(3): 233–239, 1988

    Google Scholar 

  21. Bostwick DG, Amin MB, et al.: Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 24(3): 298–310, 1993

    Google Scholar 

  22. Bostwick DG, Srigley J, et al.: Atypical adenomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 24(8): 819–832, 1993

    Google Scholar 

  23. Henneberry JM, Kahane H, et al.: The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. Am J Surg Pathol 21(6): 725–728, 1997

    Google Scholar 

  24. Anton RC, Chakraborty S, et al.: The significance of intraluminal prostatic crystalloids in benign needle biopsies. Am J Surg Pathol 22(4): 446–449, 1998

    Google Scholar 

  25. Nagle RB, Ahmann FR et al.: Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 47(1): 281–286, 1987

    Google Scholar 

  26. O'Malley FP, Grignon DJ et al.: Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 417(3): 191–196, 1990

    Google Scholar 

  27. Wojno KJ, Epstein JI: The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 19(3): 251–260, 1995

    Google Scholar 

  28. Bostwick DG, Wollan P, et al.: Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding. Arch Pathol Lab Med 119(5): 444–447, 1995

    Google Scholar 

  29. Randolph TL, Amin MB et al.: Histologic variants of adenocarcinoma and other carcinomas of prostate: Pathologic criteria and clinical significance. Mod Pathol 10(6): 612–629, 1997

    Google Scholar 

  30. Ro JY, Grignon DJ et al.: Mucinous adenocarcinoma of the prostate: Histochemical and immunohistochemical studies. Hum Pathol 21(6): 593–600, 1990

    Google Scholar 

  31. Teichman JM, Shabaik A et al.: Mucinous adenocarcinoma of the prostate and hormone sensitivity. J Urol 151(3): 701–702, 1994

    Google Scholar 

  32. Ro JY, el-Naggar A et al.: Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol 12(6): 453–460, 1988

    Google Scholar 

  33. Guerin D, Hasan N, et al.: Signet ring cell differentiation in adenocarcinoma of the prostate: A study of five cases. Histopathology 22(4): 367–371, 1993

    Google Scholar 

  34. Christensen WN, Steinberg G, et al.: Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 67(8): 2118–2124, 1991

    Google Scholar 

  35. Lee SS: Endometrioid adenocarcinoma of the prostate: A clinicopathologic and immunohistochemical study. J Surg Oncol 55(4): 235–238, 1994

    Google Scholar 

  36. Millar EK, Sharma NK et al.: Ductal (endometrioid) adenocarcinoma of the prostate: A clinicopathological study of 16 cases. Histopathology 29(1): 11–19, 1996

    Google Scholar 

  37. Tetu B, Ro JY et al.: Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 59(10): 1803–1809, 1987

    Google Scholar 

  38. Oesterling JE, Hauzeur CG et al.: Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol 147(3 Pt 2): 804–807, 1992

    Google Scholar 

  39. Rubenstein JH, Katin MJ et al.: Small cell anaplastic carcinoma of the prostate: Seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 20(4): 376–380, 1997

    Google Scholar 

  40. Shannon RL, Ro JY et al.: Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients. Cancer 69(11): 2676–2682, 1992

    Google Scholar 

  41. Lauwers GY, Schevchuk M, et al.: Carcinosarcoma of the prostate. Am J Surg Pathol 17(4): 342–349, 1993

    Google Scholar 

  42. Dundore PA, Cheville JC, et al.: Carcinosarcoma of the prostate. Report of 21 cases. Cancer 76(6): 1035–1042, 1995

    Google Scholar 

  43. Bostwick DG: Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 78(2): 330–336, 1996

    Google Scholar 

  44. Raviv G, Janssen T et al.: Prostatic intraepithelial neoplasia: Influence of clinical and pathological data on the detection of prostate cancer. J Urol 156(3): 1050–1054, discussion 1054–1055, 1996

    Google Scholar 

  45. Shepherd D, Keetch DW et al.: Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol 156(2 Pt 1): 460–462, discussion 462–463, 1996

    Google Scholar 

  46. Alsikafi NF, Brendler CB, et al.: High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone. Urology 57(2): 296–300, 2001

    Google Scholar 

  47. Borboroglu PG, Sur RL, et al.: Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 166(3): 866–870, 2001

    Google Scholar 

  48. Park S, Shinohara K et al.: Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol 165(5): 1409–1414, 2001

    Google Scholar 

  49. Kronz JD, Allan CH, et al.: Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: Data on men with more than one follow-up biopsy. Am J Surg Pathol 25(8): 1079–1085, 2001

    Google Scholar 

  50. Amin MB, Ro JY, et al.: Prostatic intraepithelial neoplasia. Relationship to adenocarcinoma of prostate. Pathol Annu 29(Pt 2): 1–30, 1994

    Google Scholar 

  51. Iczkowski KA, MacLennan GT, et al.: Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: Clinical significance in 33 cases. Am J Surg Pathol 21(12): 1489–1495, 1997

    Google Scholar 

  52. Ouyang RC, Kenwright DN et al.: The presence of atypical small acinar proliferation in prostate needle biopsy is predictive of carcinoma on subsequent biopsy. BJU Int 87(1): 70–74, 2001

    Google Scholar 

  53. Iczkowski KA, Bassler TJ, et al.: Diagnosis of suspicious for malignancy in prostate biopsies: Predictive value for cancer. Urology 51(5): 749–757, discussion 757–758, 1998

    Google Scholar 

  54. Sebo TJ, Cheville JC et al.: Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: A report of 454 cases. Cancer 91(11): 2196–2204, 2001

    Google Scholar 

  55. Egevad L, Granfors T, et al.: Prognostic value of the Gleason score in prostate cancer. BJU Int 89(6): 538–542, 2002

    Google Scholar 

  56. Nelson CP, Rubin MA et al.: Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 59(5): 740–745, 2002

    Google Scholar 

  57. Feneley MR, Partin AW: Indicators of pathologic stage of prostate cancer and their use in clinical practice. Urol Clin North Am 28(3): 443–458, 2001

    Google Scholar 

  58. D'Amico AV, Whittington R, et al.: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18(6): 1164–1172, 2000

    Google Scholar 

  59. Conrad S, Graefen M, et al.: Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 167(2 Pt 1): 521–525, 2002

    Google Scholar 

  60. Moul JW: Prostate biopsy quantitative histology as a staging and prognostic factor. J Urol 167(2 Pt 1): 526–527, 2002

    Google Scholar 

  61. Grignon DJ, Hammond EH: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Arch Pathol Lab Med 119(12): 1122–1126, 1995

    Google Scholar 

  62. Chodak GW, Thisted RA, et al.: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330(4): 242–248, 1994

    Google Scholar 

  63. Epstein JI, Pizov G, et al.: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71(11): 3582–3593, 1993

    Google Scholar 

  64. Zagars GK, Pollack A et al.: Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79(7): 1370–1380, 1997

    Google Scholar 

  65. Roach M 3rd, Lu J et al.: Long-term survival after radiotherapy alone: Radiation therapy oncology group prostate cancer trials. J Urol 161(3): 864–868, 1999

    Google Scholar 

  66. Pilepich MV, Krall JM et al.: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45(4): 616–623, 1995

    Google Scholar 

  67. Pilepich MV, Winter K et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50(5): 1243–1252, 2001

    Google Scholar 

  68. McNeal JE, Redwine EA, et al.: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12(12): 897–906, 1988

    Google Scholar 

  69. Lee F, Siders DB, et al.: Prostate cancer: transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer. Cancer 67(4 Suppl): 1132–1142, 1991

    Google Scholar 

  70. Epstein JI, Pound CR, et al.: Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 160(1): 97–100, discussion 101, 1998

    Google Scholar 

  71. Tefilli MV, Gheiler EL et al.: Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 160(3 Pt 1): 802–806, 1998

    Google Scholar 

  72. Tefilli MV, Gheiler EL et al.: Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 53(2): 372–377, 1999

    Google Scholar 

  73. Sakr WA, Tefilli MV et al.: Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 56(5): 730–734, 2000

    Google Scholar 

  74. Han M, Partin AW, et al.: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28(3): 555–565, 2001

    Google Scholar 

  75. Makarov DV, Sanderson H, et al.: Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 3 and 3 4 Independent of the Number of Involved Cores? J Urol 167(6): 2440–2442, 2002

    Google Scholar 

  76. Partin AW, Mangold LA et al.: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58(6): 843–848, 2001

    Google Scholar 

  77. Freedland SJ, Csathy GS, et al.: Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 167(2 Pt 1): 516–520, 2002

    Google Scholar 

  78. Grossklaus DJ, Coffey CS, et al.: Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 167(5): 2032–2035, discussion 2036, 2002

    Google Scholar 

  79. Grossfeld GD, Latini DM, et al.: Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: Results from CaPSURE. Urology 59(4): 560–565, 2002

    Google Scholar 

  80. Bonin SR, Hanlon AL, et al.: Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 79(1): 75–80, 1997

    Google Scholar 

  81. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152(5 Pt 2): 1837–1842, 1994

    Google Scholar 

  82. Pound CR, Partin AW et al.: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24(2): 395–406, 1997

    Google Scholar 

  83. Mian BM, Troncoso P et al.: Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 167(4): 1675–1680, 2002

    Google Scholar 

  84. Sakr WA, Grignon DJ: Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens. Urol Clin North Am 26(3): 453–463, 1999

    Google Scholar 

  85. Murphy WM, Soloway MS et al.: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68(4): 821–828, 1991

    Google Scholar 

  86. Tetu B, Srigley JR et al.: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 15(2): 111–120, 1991

    Google Scholar 

  87. Armas OA, Aprikian AG, et al.: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18(10): 979–991, 1994

    Google Scholar 

  88. Bentley G, Dey J, et al.: Significance of the Gleason scoring system after neoadjuvant hormonal therapy. Mol Urol 4(3): 125, discussion 131, 2000

    Google Scholar 

  89. Dhom G, Degro S: Therapy of prostatic cancer and histopathologic follow-up. Prostate 3(6): 531–542, 1982

    Google Scholar 

  90. Rakozy C, FJ, Tekyi-Mensah S et al.: Post-radiation prostate needle bipsies in 121 patients with and without neoadjuvant hormonal therapy: Histologic grading and clinical outcome (abstract). Mod Pathol 13: 111A, 2000

    Google Scholar 

  91. Bostwick DG, Egbert BM, et al.: Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 6(6): 541–551, 1982

    Google Scholar 

  92. Siders DB, Lee F: Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. Hum Pathol 23(4): 344–351, 1992

    Google Scholar 

  93. Crook JM, Bahadur YA, et al.: Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 79(1): 81–89, 1997

    Google Scholar 

  94. Wheeler JA, Zagars GK et al.: Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer 71(11): 3783–3787, 1993

    Google Scholar 

  95. Brawn P: Histologic features of metastatic prostate cancer. Hum Pathol 23(3): 267–272, 1992

    Google Scholar 

  96. Bubendorf L, Schopfer A, et al.: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 31(5): 578–583, 2000

    Google Scholar 

  97. Saitoh H, Hida M et al.: Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 54(12): 3078–3084, 1984

    Google Scholar 

  98. Turkeri LN, Sakr WA et al.: Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 25(4): 199–205, 1994

    Google Scholar 

  99. Gao X, Chen YQ, et al.: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11(7): 1395–1398, 1995

    Google Scholar 

  100. Gao X, Grignon DJ, et al.: Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46(2): 227–237, 1995

    Google Scholar 

  101. Macoska JA, Trybus TM, et al.: Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 55(22): 5390–5395, 1995

    Google Scholar 

  102. Sakr WA, Grignon DJ: Prostate cancer: Indicators of aggressiveness. Eur Urol 32(Suppl 3): 15–23, 1997

    Google Scholar 

  103. Sarkar FH, Li Y et al.: Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 40(4): 256–260, 1999

    Google Scholar 

  104. Dunsmuir WD, Gillett CE, et al.: Molecular markers for predicting prostate cancer stage and survival. BJU Int 86(7): 869–878, 2000

    Google Scholar 

  105. Gopalkrishnan RV, Kang DC, et al.: Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 189(3): 245–256, 2001

    Google Scholar 

  106. Mora LB, Buettner R et al.: Prostate adenocarcinoma: Cellular and molecular abnormalities. Cancer Control 8(6): 551–561, 2001

    Google Scholar 

  107. Hamdy FC: Prognostic and predictive factors in prostate cancer. Cancer Treat Rev 27(3): 143–151, 2001

    Google Scholar 

  108. Bostwick DG, Grignon DJ, et al.: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7): 995–1000, 2000

    Google Scholar 

  109. Hammond ME, Fitzgibbons PL, et al.: College of American Pathologists Conference XXXV: Solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med 124(7): 958–965, 2000

    Google Scholar 

  110. Luo JH, Yu YP, et al.: Gene expression analysis of prostate cancers. Mol Carcinog 33(1): 25–35, 2002

    Google Scholar 

  111. Veltri RW, Miller MC et al.: Prediction of prostate carcinoma stage by quantitative biopsy pathology. Cancer 91(12): 2322–2328, 2001

    Google Scholar 

  112. Sebo TJ, Cheville JC et al.: Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 26(4): 431–439, 2002

    Google Scholar 

  113. Roach M, Lu J et al.: Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47(3): 609–615, 2000

    Google Scholar 

  114. Tran TA, Jennings TA et al.: Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: A distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. Am J Surg Pathol 22(3): 347–354, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Wayne State University School of Medicine, Karmanos Cancer Institute, USA

    Mingxin Che

  2. Detroit Medical Center, Detroit, MI, USA

    David Grignon

Authors
  1. Mingxin Che
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Grignon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Che, M., Grignon, D. Pathology of Prostate Cancer. Cancer Metastasis Rev 21, 381–396 (2002). https://doi.org/10.1023/A:1021242813374

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021242813374

Search

Navigation